Bobby Sheng, Bora Pharmaceuticals CEO

Taipei's Bo­ra wants in on the CD­MO game as re­port shows plen­ty of room for in­dus­try growth

Taipei’s Bo­ra Phar­ma­ceu­ti­cals has linked up with Taishin Health­care to in­vest about $108 mil­lion in­to CD­MOs and CROs in re­sponse to a boom­ing busi­ness en­vi­ron­ment for both in­dus­tries.

The two com­pa­nies plan to en­ter the macro­mol­e­c­u­lar, and cell and gene ther­a­py man­u­fac­tur­ing spaces, and strength­en com­pet­i­tive­ness while bol­ster­ing Tai­wan’s CD­MO mar­ket. Ac­cord­ing to a re­port from Hart­ford, CT-based re­search group Glob­al In­for­ma­tion, the glob­al CD­MO mar­ket was val­ued at $160.1 bil­lion in 2020 and could grow to as much as $242.64 bil­lion by 2026. There are five CD­MOs in the world that have rev­enue above $500 mil­lion, while 75% of the field takes in less than $50 mil­lion in rev­enue, the re­port says.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.